These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1243985)

  • 1. Bioavailability of four brands of phenytoin tablets.
    Pentikäinen PJ; Neuvonen PJ; Elfving SM
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):213-8. PubMed ID: 1243985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting the bioavailability of phenytoin.
    Neuvonen PJ; Pentikäinen PJ; Elfving SM
    Int J Clin Pharmacol Biopharm; 1977 Feb; 15(2):84-9. PubMed ID: 577918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma level studies on different brands of sodium diphenylhydantoin (DPH) and primidone.
    Borst SI; Lockwood CH
    Int J Clin Pharmacol Biopharm; 1975 Oct; 12(3):309-14. PubMed ID: 1242131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable-isotope methodology for the bioavailability study of phenytoin during multiple-dosing regimens.
    Kasuya Y; Mamada K; Baba S; Matsukura M
    J Pharm Sci; 1985 May; 74(5):503-7. PubMed ID: 4020625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of three phenytoin preparations in healthy subjects and in epileptics.
    Rambeck B; Boenigk HE; Stenzel E
    Eur J Clin Pharmacol; 1977 Dec; 12(4):285-90. PubMed ID: 579344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dissolution rates and bioavailability of phenytoin preparations (author's transl)].
    Brandau R; Wehnert HU
    Arzneimittelforschung; 1979; 29(3):552-5. PubMed ID: 582744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma phenytoin levels produced by various phenytoin preparations.
    Sansom LN; O'Reilly WJ; Wiseman CW; Stern LM; Derham J
    Med J Aust; 1975 Oct; 2(15):593-5. PubMed ID: 1105111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bioavailability of phenytoin.
    Gugler R; Fröscher W; Eichelbaum M; Hildenbrand G
    J Neurol; 1977 Oct; 216(3):155-62. PubMed ID: 72133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the bioavailability of Polfa phenytoin tablets].
    Lazowski J; Lypka A; Zadrozyńska E; Pakszys W
    Neurol Neurochir Pol; 1978; 12(3):251-5. PubMed ID: 683430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single dose comparison of the relative bioavailability of phenytoin suspension and extended capsules.
    Fitzsimmons WE; Garnett WR; Comstock TJ; Pellock JM
    Epilepsia; 1986; 27(4):464-8. PubMed ID: 3720707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of formulation on dissolution and bioavailability of phenytoin tablets.
    Chakrabarti S; Belpaire F; Moerman E
    Pharmazie; 1980; 35(10):627-9. PubMed ID: 7454745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of three formulations of diphenylhydantoin in the dog.
    Overduin LM; van Gogh H; Mol JA; van Nes JJ
    Res Vet Sci; 1989 Mar; 46(2):271-3. PubMed ID: 2704892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of increased bioavailability of phenytoin tablets on serum phenytoin concentration in epileptic out-patients.
    Neuvonen PJ; Bardy A; Lehtovaara R
    Br J Clin Pharmacol; 1979 Jul; 8(1):37-41. PubMed ID: 552295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of phenytoin from various pharmaceutical preparations in children.
    Manson JI; Beal SM; Magarey A; Pollard AC; O'Reilly WJ; Sansom LN
    Med J Aust; 1975 Oct; 2(15):590-2. PubMed ID: 1196223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of phenytoin. A comparison of two preparations.
    Stewart MJ; Ballinger BR; Devlin EJ; Miller AY; Ramsay AC
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):209-12. PubMed ID: 1243984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of phenytoin availability from pharmaceutical preparations].
    Leucuţa SE; Almaşu I
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1986; 31(4):273-82. PubMed ID: 2951832
    [No Abstract]   [Full Text] [Related]  

  • 18. [Serum diphenylhydantoin in epileptic patients (preliminary report)].
    Radzikowska B; Zadrozyńska E; Pakszys W
    Neurol Neurochir Pol; 1977; 11(5):551-4. PubMed ID: 593505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability and dissolution of proprietary and generic formulations of phenytoin.
    Soryal I; Richens A
    J Neurol Neurosurg Psychiatry; 1992 Aug; 55(8):688-91. PubMed ID: 1527539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin in phenytoin-treated patients.
    Hoppel C; Garle M; Rane A; Sjöqvist F
    Clin Pharmacol Ther; 1977 Mar; 21(3):294-300. PubMed ID: 837648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.